Evidence map›Paper›PMID 33816285›Full record

ArticleFrontiers in oncology2021

POLE and Mismatch Repair Status, Checkpoint Proteins and Tumor-Infiltrating Lymphocytes in Combination, and Tumor Differentiation: Identify Endometrial Cancers for Immunotherapy.

Dandan Dong, Huajiang Lei, Duanya Liu, Hansong Bai, Yue Yang, Baijie Tang, Ke Li, Juan Liu, Gang Xu, Xue Xiao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Dandan DongDepartment of Pathology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Huajiang LeiChinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
Duanya LiuDepartment of Pathology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Hansong BaiDepartment of Pathology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Yue YangDepartment of Pathology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Baijie TangDepartment of Pathology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Ke LiDepartment of Pathology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Juan LiuDepartment of Pathology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Gang XuDepartment of Pathology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Xue XiaoDepartment of Pathology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
University of Electronic Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAlthough Polymerase-epsilon (POLE)-mutated and mismatch repair (MMR)-deficient endometrial cancers (ECs) are considered as promising candidates for anti-PD-1/PD-L1 therapy, selecting only these patients may exclude other patients who could potentially respond to this treatment strategy, highlighting the need of additional biomarkers for better patient selection. This study aims to evaluate potential predictive biomarkers for anti-PD-1/PD-L1 therapy in addition to POLE mutation (POLEm) and MMR deficiency (MMRd).

methodsWe performed next generation sequencing for POLE from 202 ECs, and immunohistochemistry for MLH1, MSH2, MSH6, PMS2, CD3, CD8, PD-1 and PD-L1 on full-section slides from these ECs. We assessed the association of POLEm and MMRd with clinicopathologic features, expression of check point proteins, and density of tumor-infiltrating lymphocytes (TILs). Prognostic impact of these immune markers was also evaluated.

resultsPOLEm, MMRd and high-grade tumors exhibited elevated level of TILs. Increased expression of PD-1 and PD-L1 was observed in MMRd and high-grade ECs. A subgroup of MMR proficient ECs also harbored increased density of TILs, and positive expression of PD-1 and PD-L1. In addition, negative expression of checkpoint proteins and high density of TILs in combination was associated with good prognosis.

conclusionsCandidates for PD-1 blockade may extend beyond POLEm and MMRd ECs, additional factors such as tumor grade, and combination of TILs levels and expression of checkpoint proteins may need to be considered for better patient selection.

Indexed as

endometrial cancerimmunotherapymismatch repair deficiencyPD-1PD-L1POLE

Identifiers

PMID33816285
PMCPMC8017289
OpenAlexW3138580204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.